Pricing
  1. US-listed companies
  2. FILANA THERAPEUTICS, INC.
  3. Financials
  4. Stock-based compensation

FILANA THERAPEUTICS, INC.【FLNA】

Market cap
$106.76M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202416+255.23%
Dec 31, 20235+121.97%
Dec 31, 20222+17.45%
Dec 31, 20212+78.04%
Dec 31, 20201-23.77%
Dec 31, 20191-45.73%
Dec 31, 20182-19.68%
Dec 31, 20173-31.40%
Dec 31, 20164+25.37%
Dec 31, 20153-8.08%
Dec 31, 20144+21.28%
Dec 31, 20133-53.09%
Dec 31, 20127+21.78%
Dec 31, 20115

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)